Blind Michael, Blank Michael
AptaIT GmbH, Munich, Germany.
AptaIT GmbH, Munich, Germany.
Mol Ther Nucleic Acids. 2015;4(1):e223. doi: 10.1038/mtna.2014.74. Epub 2016 Dec 6.
Over the last decade, aptamers have begun to find their way from basic research to diverse commercial applications. The development of diagnostics is even more widespread than clinical applications because aptamers do not have to be extensively modified to enhance their in vivo stability and pharmacokinetics in diagnostic assays. The increasing attention has propelled the technical progress of the in vitro selection technology (SELEX) to enhance the efficiency of developing aptamers for commercially interesting targets. This review highlights recent progress in the technical steps of a SELEX experiment with a focus on high-throughput next-generation sequencing and bioinformatics. Achievements have been made in the optimization of aptamer libraries, separation schemes, amplification of the selected libraries and the identification of aptamer sequences from enriched libraries.
在过去十年中，适体已开始从基础研究走向各种商业应用。诊断领域的发展比临床应用更为广泛，因为在诊断分析中，适体无需进行大量修饰来提高其体内稳定性和药代动力学。日益增加的关注推动了体外筛选技术（SELEX）的技术进步，以提高针对具有商业价值靶点开发适体的效率。本综述重点介绍了SELEX实验技术步骤的最新进展，尤其关注高通量下一代测序和生物信息学。在适体文库优化、分离方案、所选文库的扩增以及从富集文库中鉴定适体序列方面均取得了成果。
